Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
dc.contributor.author | Kissling, Esther | |
dc.contributor.author | Hooiveld, Mariette | |
dc.contributor.author | Sandonis Martín, Virginia | |
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | William, Naoma | |
dc.contributor.author | Vilcu, Ana-Maria | |
dc.contributor.author | Mazagatos, Clara | |
dc.contributor.author | Domegan, Lisa | |
dc.contributor.author | de Lusignan, Simon | |
dc.contributor.author | Meijer, Adam | |
dc.contributor.author | Machado, Ausenda | |
dc.contributor.author | Brytting, Mia | |
dc.contributor.author | Casado, Itziar | |
dc.contributor.author | Murray, Josephine-L K | |
dc.contributor.author | Belhillil, Sylvie | |
dc.contributor.author | Larrauri, Amparo | |
dc.contributor.author | O'Donnell, Joan | |
dc.contributor.author | Tsang, Ruby | |
dc.contributor.author | de Lange, Marit | |
dc.contributor.author | Rodrigues, Ana Paula | |
dc.contributor.author | Riess, Maximilian | |
dc.contributor.author | Castilla, Jesús | |
dc.contributor.author | Hamilton, Mark | |
dc.contributor.author | Falchi, Alessandra | |
dc.contributor.author | Pozo, Francisco | |
dc.contributor.author | Dunford, Linda | |
dc.contributor.author | Cogdale, Jade | |
dc.contributor.author | Jansen, Tessa | |
dc.contributor.author | Guiomar, Raquel | |
dc.contributor.author | Enkirch, Theresa | |
dc.contributor.author | Burgui, Cristina | |
dc.contributor.author | Sigerson, Debbie | |
dc.contributor.author | Blanchon, Thierry | |
dc.contributor.author | Martínez Ochoa, Eva María | |
dc.contributor.author | Connell, Jeff | |
dc.contributor.author | Ellis, Joanna | |
dc.contributor.author | van Gageldonk-Lafeber, Rianne | |
dc.contributor.author | Kislaya, Irina | |
dc.contributor.author | Rose, Angela Mc | |
dc.contributor.author | Valenciano, Marta | |
dc.date.accessioned | 2021-08-02T12:46:22Z | |
dc.date.available | 2021-08-02T12:46:22Z | |
dc.identifier.pmid | 34296676 | |
dc.identifier.doi | 10.2807/1560-7917.ES.2021.26.29.2100670 | |
dc.identifier.uri | http://hdl.handle.net/10029/625207 | |
dc.language.iso | en | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Europe | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | multicentre study | en_US |
dc.subject | test-negative design | en_US |
dc.subject | vaccine effectiveness | en_US |
dc.title | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. | en_US |
dc.type | Article | en_US |
dc.type | Other | en_US |
dc.identifier.eissn | 1560-7917 | |
dc.identifier.journal | Euro Surveill 2021; 26(29):pii.2100670 | en_US |
dc.source.journaltitle | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin | |
dc.source.volume | 26 | |
dc.source.issue | 29 | |
dc.source.country | Sweden |